The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

References

• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi:10.1038/jid.2012.339
   PubMed Web of Science ®Google Scholar
• Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21(3):170–173. doi:10.7861/clinmed.2021-0257
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Ruggiero A, et al. Use of biological therapies for the management of pustular psoriasis: a new era? Clin Cosmet Invest Dermatol. 2023;16:1677–1690. doi:10.2147/CCID.S407812
   PubMed Web of Science ®Google Scholar
• Yousaf A, Raiker R, Davis SM, Gayam S, Zinn Z. Association between psoriasis, psoriatic arthritis and gastrointestinal disease: an exploratory nationwide inpatient sample analysis. Wien Klin Wochenschr. 2021;133(11–12):586–593. doi:10.1007/s00508-020-01740-8
   PubMed Web of Science ®Google Scholar
• Megna M, Ocampo-Garza SS, Potestio L, et al. New-onset psoriatic arthritis under biologics in psoriasis patients: an increasing challenge? Biomedicines. 2021;9(10):1482. doi:10.3390/biomedicines9101482
   PubMed Web of Science ®Google Scholar
• Amanat M, Salehi M, Rezaei N. Neurological and psychiatric disorders in psoriasis. Rev Neurosci. 2018;29(7):805–813. doi:10.1515/revneuro-2017-0108
   PubMed Web of Science ®Google Scholar
• Branisteanu DE, Cojocaru C, Diaconu R, et al. Update on the etiopathogenesis of psoriasis (Review). Exp Ther Med. 2022;23(3):201. doi:10.3892/etm.2022.11124
   PubMed Web of Science ®Google Scholar
• Muhr P, Zeitvogel J, Heitland I, Werfel T, Wittmann M. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol. 2011;165(1):189–193. doi:10.1111/j.1365-2133.2011.10302.x
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Megna M. Paradoxical reactions to biologicals for psoriasis. Expert Opin Biol Ther. 2022;22(12):1435–1437. doi:10.1080/14712598.2022.2153593
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Stuart PE, Tian C, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8:15382. doi:10.1038/ncomms15382
   PubMed Web of Science ®Google Scholar
• Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73. doi:10.1016/j.jaut.2015.07.008
   PubMed Web of Science ®Google Scholar
• Morizane S, Gallo RL. Antimicrobial peptides in the pathogenesis of psoriasis. J Dermatol. 2012;39(3):225–230. doi:10.1111/j.1346-8138.2011.01483.x
   PubMed Web of Science ®Google Scholar
• Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339–1350. doi:10.1038/jid.2009.59
   PubMed Web of Science ®Google Scholar
• Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577–2587. doi:10.1084/jem.20060244
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379–390. doi:10.1007/s12016-018-8702-3
   PubMed Web of Science ®Google Scholar
• Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252–2262. doi:10.4049/jimmunol.1201505
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22(1):25–41. doi:10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22(1):43–58. doi:10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Wechter T, Cline A, Feldman SR. Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab. Ther Clin Risk Manag. 2018;14:1489–1497. doi:10.2147/TCRM.S177127
   PubMed Web of Science ®Google Scholar
• Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125–130. doi:10.1084/jem.20030451
   PubMed Web of Science ®Google Scholar
• Liu W, Ouyang X, Yang J, et al. AP-1 activated by toll-like receptors regulates expression of IL-23 p19. J Biol Chem. 2009;284(36):24006–24016. doi:10.1074/jbc.M109.025528
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Saraceno R, Chimenti MS, Guttman-Yassky E, Krueger JG. Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target? Expert Opin Ther Targets. 2014;18(5):513–525. doi:10.1517/14728222.2014.889686
   PubMed Web of Science ®Google Scholar
• Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–1914. doi:10.1074/jbc.M207577200
   PubMed Web of Science ®Google Scholar
• Megna M, Balato A, Raimondo A, Balato N. Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther. 2018;18(4):459–468. doi:10.1080/14712598.2018.1445223
   PubMed Web of Science ®Google Scholar
• A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis (VOYAGE 1). Available from https://clinicaltrials.gov/study/NCT02207231?cond=psoriasis&term=(NCT02207231)&rank=1. Accessed January 18, 2024.
   Google Scholar
• A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis with randomized withdrawal and retreatment (VOYAGE 2). Available from: https://clinicaltrials.gov/study/NCT02207244?cond=psoriasis&term=(NCT02207244)&rank. Accessed April 08, 2024.
   Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi:10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with Adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. doi:10.1016/j.jaad.2016.11.042
   PubMed Web of Science ®Google Scholar
• Reich K, Gordon KB, Strober BE, et al. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021;185(6):1146–1159. doi:10.1111/bjd.20568
   PubMed Web of Science ®Google Scholar
• A study of guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab (NAVIGATE). Available from: https://clinicaltrials.gov/study/NCT02203032?cond=psoriasis&term=(NCT02203032)&rank=1. Accessed April 08, 2024.
   Google Scholar
• Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114–123. doi:10.1111/bjd.15750
   PubMed Web of Science ®Google Scholar
• A study to evaluate the comparative efficacy of CNTO 1959 (Guselkumab) and secukinumab for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE). Available from: https://clinicaltrials.gov/study/NCT03090100?cond=psoriasis&term=(NCT03090100)&. Accessed April 08, 2024.
   Google Scholar
• Thaçi D, Pinter A, Sebastian M, et al. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Br J Dermatol. 2020;183(2):265–275. doi:10.1111/bjd.18696
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J DermatolTreat. 2022;33:1–18. doi:10.1080/09546634.2022.2036674
   Google Scholar
• Solak EÖ, Aba FC, Çınar SL, Kartal D, Borlu M. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: a single-center study from Turkey. J Cosmet Dermatol. 2024. doi:10.1111/jocd.16260
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Marcelli L, Vellucci L, et al. Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks. Expert Opin Biol Ther. 2023;23(4):371–381. doi:10.1080/14712598.2023.2194485
   PubMed Web of Science ®Google Scholar
• Yang J, Hu K, Li X, et al. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 52 weeks: a retrospective, observational, multicenter study from China. Dermatol Ther. 2023;13(2):477–485. doi:10.1007/s13555-022-00869-w
   Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Real-life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: a 104-week multicenter retrospective study - IL PSO (Italian LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2023;37(5):1017–1027. doi:10.1111/jdv.18913
   PubMed Web of Science ®Google Scholar
• Gu C, Yang J. Risankizumab for the treatment of psoriasis. Expert Rev Clin Pharmacol. 2019;12(9):851–857. doi:10.1080/17512433.2019.1657829
   PubMed Web of Science ®Google Scholar
• Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L. Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med. 2023;12(9):3233. doi:10.3390/jcm12093233
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Effectiveness, tolerability, and drug survival of risankizumab in a real-world setting: a three-year retrospective multicenter study-IL PSO (Italian LANDSCAPE PSORIASIS). J Clin Med. 2024;13(2):495. doi:10.3390/jcm13020495
   PubMed Web of Science ®Google Scholar
• Gönülal M, Balcı DD, Öztürkcan S. Risankizumab for the treatment of the patients with moderate to severe plaque psoriasis during a 24-week period: real-life experience. Clin Cosmet Invest Dermatol. 2023;16:3653–3659. doi:10.2147/CCID.S442427
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. A risankizumab super responder profile identified by long-term real-life observation-IL PSO (Italian LANDSCAPE PSORIASIS). J Eur Acad Dermatol Venereol. 2024;38(1):e113–e116. doi:10.1111/jdv.19464
   PubMedGoogle Scholar
• Megna M, Ruggiero A, Salsano A, et al. A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab. Clin Cosmet Invest Dermatol. 2023;16:3503–3507. doi:10.2147/CCID.S447123
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA dermatol. 2020;156(6):649–658. doi:10.1001/jamadermatol.2020.0723
   PubMed Web of Science ®Google Scholar
• Papp KA, Blauvelt A, Puig L, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89(6):1149–1158. doi:10.1016/j.jaad.2023.07.1024
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with Adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. doi:10.1016/S0140-6736(19)30952-3
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–59. doi:10.1111/bjd.19341
   PubMed Web of Science ®Google Scholar
• Thaçi D, Soliman AM, Eyerich K, et al. Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. J Eur Acad Dermatol Venereol. 2021;35(8):1686–1691. doi:10.1111/jdv.17109
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse). Br J Dermatol. 2023;189(5):540–552. doi:10.1093/bjd/ljad252
   PubMed Web of Science ®Google Scholar
• Markham A. Tildrakizumab: first Global Approval. Drugs. 2018;78(8):845–849. doi:10.1007/s40265-018-0917-3
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis (MK-3222-010) (reSURFACE 1). Available from: https://clinicaltr. Accessed April 08, 2024.
   Google Scholar
• A Study to Evaluate the Efficacy and Safety. Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in participants with moderate-to-severe chronic plaque psoriasis followed by a long-term extension study (MK-3222-011) (reSURFACE 2); 2020.
   Google Scholar
• Näslund-Koch C, Zachariae C, Skov L. Tildrakizumab: an evidence-based review of its use in the treatment of moderate-to-severe chronic plaque psoriasis. Ther Clin Risk Manag. 2020;16:903–916. doi:10.2147/TCRM.S227880
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276–288. doi:10.1016/S0140-6736(17)31279-5
   PubMed Web of Science ®Google Scholar
• Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7. doi:10.1016/j.jaci.2015.01.018
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Camela E, Potestio L, Fabbrocini G, Megna M. Drug safety evaluation of tildrakizumab for psoriasis: a review of the current knowledge. Expert Opin Drug Saf. 2022;21(12):1445–1451. doi:10.1080/14740338.2022.2160447
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M. Tildrakizumab for the treatment of moderate-to-severe psoriasis: results from 52 weeks real-life retrospective study. Clin Cosmet Invest Dermatol. 2023;16:529–536. doi:10.2147/CCID.S402183
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Cacciapuoti S, et al. Tildrakizumab for the treatment of moderate to severe psoriasis: results from a single center preliminary real-life study. Dermatol Ther. 2022;35(12):e15941. doi:10.1111/dth.15941
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Fabbrocini G, Cinelli E. Tildrakizumab: a new therapeutic option for erythrodermic psoriasis? Dermatol Ther. 2021;34:e15030. doi:10.1111/dth.15030
   PubMed Web of Science ®Google Scholar
• Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, et al. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: a retrospective, observational, multicentre study by the Spanish psoriasis group. J Eur Acad Dermatol Venereol. 2023;37(12):2517–2525. doi:10.1111/jdv.19468
   PubMed Web of Science ®Google Scholar
• Mastorino L, Cariti C, Susca S, et al. Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement. Dermatol Ther. 2022;35(11):e15818. doi:10.1111/dth.15818
   PubMed Web of Science ®Google Scholar
• Campione E, Lambiase S, Gaeta Shumak R, et al. A real-life study on the use of tildrakizumab in psoriatic patients. Pharmaceuticals. 2023;16(4):526. doi:10.3390/ph16040526
   Web of Science ®Google Scholar
• Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10. doi:10.7573/dic.2021-2-6
   Google Scholar
• Orsini D, Caldarola G, Dattola A, et al. Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study). J DermatolTreat. 2024;35(1):2319304. doi:10.1080/09546634.2024.2319304
   Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709. doi:10.1016/S0140-6736(17)30570-6
   PubMed Web of Science ®Google Scholar
• Woods RH. Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS). Br J Clin Pharmacol. 2023;89(8):2386–2395. doi:10.1111/bcp.15581
   PubMed Web of Science ®Google Scholar
• Sinvhal R, Krueger WS, Kilpatrick RD, Coppola D. Letter to the editor concerning the article: “Potential cerebrovascular accident signal for risankizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)”. Br J Clin Pharmacol. 2023;89(8):2639–2641. doi:10.1111/bcp.15746
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol. 2008;159(5):1092–1102. doi:10.1111/j.1365-2133.2008.08769.x
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271–2279. doi:10.1084/jem.20061308
   PubMed Web of Science ®Google Scholar
• Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012;21(2):104–110. doi:10.1111/j.1600-0625.2011.01412.x
   PubMed Web of Science ®Google Scholar
• Deodhar A, Mease PJ, McInnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21(1):111. doi:10.1186/s13075-019-1882-2
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Cinelli E, Fabbrocini G. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2020;45(7):848–852. doi:10.1111/ced.14258
   PubMed Web of Science ®Google Scholar
• Kaçar N, Balcı DD, Doğan S, Türkmen M, Gönülal M, Çınar G. Real-life efficacy and drug continuation of secukinumab in treating moderate to severe plaque psoriasis in Aegean region of Turkey: a multicenter retrospective study and systematic review of the literature. Asian Pacific J Allergy Immunol. 2022. doi:10.12932/AP-241021-1259
   PubMedGoogle Scholar
• Muñoz-Aceituno E, Butrón-Bris B, Ovejero-Benito MC, et al. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice. J Eur Acad Dermatol Venereol. 2023. doi:10.1111/jdv.19782
   PubMed Web of Science ®Google Scholar
• Thaçi D, Körber A, von Kiedrowski R, et al. Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. J Eur Acad Dermatol Venereol. 2020;34(2):310–318. doi:10.1111/jdv.15962
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Atzori L, et al. Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study. Expert Opin Biol Ther. 2022;22(4):547–554. doi:10.1080/14712598.2022.2029841
   PubMed Web of Science ®Google Scholar
• Pellegrini C, Esposito M, Rossi E, et al. Secukinumab in patients with psoriasis and a personal history of malignancy: a multicenter real-life observational study. Dermatol Ther. 2022;12(11):2613–2626. doi:10.1007/s13555-022-00797-9
   Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338. doi:10.1056/NEJMoa1314258
   PubMed Web of Science ®Google Scholar
• Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year (ERASURE). Available from: https://clinicaltrials.gov/study/NCT01365455?cond=psoriasis&term=(NCT01365455)&rank=1. Accessed January 10, 2024.
   Google Scholar
• Safety and efficacy of secukinumab compared to etanercept in subjects with moderate to severe, chronic plaque-type psoriasis (FIXTURE). Available from: https://clinicaltrials.gov/study/NCT01358578?cond=psoriasis&term=(NCT01358578)&rank=1. Accessed January 10, 2024.
   Google Scholar
• Armstrong AW, Papp K, Kircik L. Secukinumab: review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR. J Clin Aesthet Dermatol. 2016;9(6 Suppl 1):1.
   Google Scholar
• Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–409. doi:10.1016/j.jaad.2015.05.013
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018;32(9):1507–1514. doi:10.1111/jdv.14878
   PubMed Web of Science ®Google Scholar
• Extension study of secukinumab prefilled syringes in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab. Available from https://clinicaltrials.gov/study/NCT01544595?cond=pso. Accessed April 08, 2024.
   Google Scholar
• Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50. doi:10.2147/JIR.S100940
   PubMed Web of Science ®Google Scholar
• A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-1.) Available from: https://clinicaltrials.gov/study/NCT01474512?cond=psoriasis&term=(NCT01474512)&rank=1. Accessed January 13, 2024.
   Google Scholar
• A phase 3 study in participants with moderate to severe psoriasis (UNCOVER-2) (UNCOVER-2). Available from: https://clinicaltrials.gov/study/NCT01597245?cond=psoriasis&term=(NCT01597245)&rank=1. Accessed April 08, 2024.
   Google Scholar
• A study in participants with moderate to severe psoriasis (UNCOVER-3) (UNCOVER-3). Available from: https://clinicaltrials.gov/study/NCT01646177?cond=psoriasis&term=(NCT01646177)&rank=1. Accessed January 18, 2024.
   Google Scholar
• Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102. doi:10.1056/NEJMc1610828
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360–368. doi:10.1016/j.jaad.2020.11.022
   PubMed Web of Science ®Google Scholar
• Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther. 2020;10(3):431–447. doi:10.1007/s13555-020-00367-x
   PubMed Web of Science ®Google Scholar
• Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177(4):1014–1023. doi:10.1111/bjd.15666
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35:e15667. doi:10.1111/dth.15667
   PubMed Web of Science ®Google Scholar
• Caldarola G, Chiricozzi A, Megna M, et al. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opin Biol Ther. 2023;23(4):365–370. doi:10.1080/14712598.2023.2193288
   PubMed Web of Science ®Google Scholar
• Malagoli P, Dapavo P, Pavia G, et al. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: a 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis). Dermatol Ther. 2022;35(8):e15608. doi:10.1111/dth.15608
   PubMed Web of Science ®Google Scholar
• Calianno G, Esposito M, Fidanza R, Palmieri M, Fargnoli MC. Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: a 24-week real-life experience. Dermatol Ther. 2021;34(4):e14993. doi:10.1111/dth.14993
   PubMed Web of Science ®Google Scholar
• Cariti C, Dapavo P, Mastorino L, et al. Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients. J Eur Acad Dermatol Venereol. 2022;36(3):e233–e235. doi:10.1111/jdv.17766
   PubMed Web of Science ®Google Scholar
• Roman M, Chiu MW. Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy. Drug Des Devel Ther. 2017;11:2065–2075. doi:10.2147/DDDT.S113683
   PubMed Web of Science ®Google Scholar
• Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–286. doi:10.1111/bjd.14493
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi:10.1056/NEJMoa1503824
   PubMed Web of Science ®Google Scholar
• Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183(6):1037–1048. doi:10.1111/bjd.19132
   PubMed Web of Science ®Google Scholar
• Mastorino L, Cariti C, Susca S, et al. Brodalumab efficacy in bio-naïve psoriasis patients: real-life experience of 202 subjects up to 48 weeks. J DermatolTreat. 2022;33(8):3211–3213. doi:10.1080/09546634.2022.2125265
   Google Scholar
• Galluzzo M, Caldarola G, De Simone C, et al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299–1310. doi:10.1080/14712598.2021.1941862
   PubMed Web of Science ®Google Scholar
• Fargnoli MC, Esposito M, Dapavo P, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35(3):693–700. doi:10.1111/jdv.16931
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front Med. 2023;10:1196966. doi:10.3389/fmed.2023.1196966
   Web of Science ®Google Scholar
• Gaudet V, Yap B, Hassan S, Barbeau M. Brodalumab for plaque psoriasis: a Canadian real-world experience at 2-years post-launch. J Cutan Med Surg. 2023;27(3):226–235. doi:10.1177/12034754231168851
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Martora F, Villani A, Comune R, Megna M. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22:355–362. doi:10.1080/14740338.2023.2218086
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med. 2023;10:1243843. doi:10.3389/fmed.2023.1243843
   Web of Science ®Google Scholar
• Valenti M, Gargiulo L, Ibba L, Pavia G, Narcisi A, Costanzo A. Sub-erythrodermic psoriasis successfully treated with bimekizumab: a case report. Dermatol Ther. 2022;35(12):e15952. doi:10.1111/dth.15952
   PubMed Web of Science ®Google Scholar
• Megna M, Battista T, Potestio L, et al. A case of erythrodermic psoriasis rapidly and successfully treated with Bimekizumab. J Cosmet Dermatol. 2023;22(3):1146–1148. doi:10.1111/jocd.15543
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, Kanda N. Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: a single-center retrospective study. J Dermatol. 2024. doi:10.1111/1346-8138.17186
   Google Scholar
• Orsini D, Malagoli P, Balato A, et al. Bimekizumab for the treatment of plaque psoriasis with involvement of genitalia: a 16-week multicenter real-world experience - IL PSO (Italian Landscape Psoriasis). Dermatol Pract Concept. 2024. doi:10.5826/dpc.1402a52
   Google Scholar
• Cirone KD, Lovegrove FE. Real-world experience using bimekizumab for the treatment of moderate-to-severe psoriasis from a single outpatient dermatology clinic. J Cutan Med Surg. 2024;28(1):78–79. doi:10.1177/12034754231217205
   PubMed Web of Science ®Google Scholar
• Papp KA, Merola JF, Gottlieb AB, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277–286.e10. doi:10.1016/j.jaad.2018.03.037
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Merola JF, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020;83(5):1367–1374. doi:10.1016/j.jaad.2020.05.105
   PubMed Web of Science ®Google Scholar
• Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475–486. doi:10.1016/S0140-6736(21)00126-4
   PubMed Web of Science ®Google Scholar
• Griffith SK, Ahn GS, Wu JJ. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021;385(12):1149–1150. doi:10.1056/NEJMc2113092
   PubMed Web of Science ®Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2
   PubMed Web of Science ®Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152. doi:10.1056/NEJMoa2102383
   PubMed Web of Science ®Google Scholar
• Farahnik B, Beroukhim K, Zhu TH, et al. Ixekizumab for the treatment of psoriasis: a review of phase III trials. Dermatol Ther. 2016;6(1):25–37. doi:10.1007/s13555-016-0102-0
   PubMed Web of Science ®Google Scholar
• Burisch J, Eigner W, Schreiber S, et al. Risk for development of inflammatory bowel disease under inhibition of interleukin 17: a systematic review and meta-analysis. PLoS One. 2020;15(5):e0233781. doi:10.1371/journal.pone.0233781
   PubMed Web of Science ®Google Scholar
• Deng Z, Wang S, Wu C, Wang C. IL-17 inhibitor-associated inflammatory bowel disease: a study based on literature and database analysis. Front Pharmacol. 2023;14:1124628. doi:10.3389/fphar.2023.1124628
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan B, Vermeire S, et al. A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe crohn’s disease. Am J Gastroenterol. 2016;111(11):1599–1607. doi:10.1038/ajg.2016.298
   PubMed Web of Science ®Google Scholar
• Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61(12):1693–1700. doi:10.1136/gutjnl-2011-301668
   PubMed Web of Science ®Google Scholar
• Schreiber S, Colombel JF, Feagan BG, et al. Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis. 2019;78(4):473–479. doi:10.1136/annrheumdis-2018-214273
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Papp KA, Marangell LB, et al. Psychiatric adverse events during treatment with brodalumab: analysis of psoriasis clinical trials. J Am Acad Dermatol. 2018;78(1):81–89.e5. doi:10.1016/j.jaad.2017.08.024
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Pallotta S, Megna M, Naidu SS. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32:1–16. doi:10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;1–3. doi:10.1080/14712598.2022.2113872
   Web of Science ®Google Scholar
• Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425–442. doi:10.1007/s40257-021-00603-w
   PubMed Web of Science ®Google Scholar
• Mastorino L, Dapavo P, Avallone G, et al. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J DermatolTreat. 2022;33(5):2495–2502. doi:10.1080/09546634.2021.1970706
   Google Scholar
• Torres T, Chiricozzi A, Puig L, et al. Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study. Am J Clin Dermatol. 2024;25(2):333–342. doi:10.1007/s40257-024-00845-4
   PubMed Web of Science ®Google Scholar
• Molinelli E, Campanati A, Brisigotti V, Offidani A. Biologic Therapy in Psoriasis (Part II): efficacy and safety of new treatment targeting IL23/IL-17 Pathways. Curr Pharm Biotechnol. 2017;18(12):964–978. doi:10.2174/1389201019666180103140643
   PubMed Web of Science ®Google Scholar
• Megna M, Potestio L, Battista T, et al. Immune response to Covid-19 mRNA vaccination in psoriasis patients undergoing treatment with biologics. Clin Exp Dermatol. 2022;47:2310–2312. doi:10.1111/ced.15395
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Sayad B, Rahimi Z. COVID-19 and psoriasis: biologic treatment and challenges. J DermatolTreat. 2022;33(2):699–703. doi:10.1080/09546634.2020.1789051
   Google Scholar
• Potestio L, Genco L, Villani A, et al. Reply to ‘Cutaneous adverse effects of the available COVID −19 vaccines in India: a questionnaire-based study’. J Eur Acad Dermatol Venereol. 2022;36. doi:10.1111/jdv.18341
   Web of Science ®Google Scholar
• Martora F, Villani A, Marasca C, Fabbrocini G, Potestio L. Skin reaction after SARS-CoV-2 vaccines Reply to “cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience”. J Eur Acad Dermatol Venereol. 2023;37(1):e43–e44. doi:10.1111/jdv.18531
   PubMed Web of Science ®Google Scholar
• Martora F, Villani A, Battista T, Fabbrocini G, Potestio L. COVID-19 vaccination and inflammatory skin diseases. J Cosmet Dermatol. 2023;22(1):32–33. doi:10.1111/jocd.15414
   PubMed Web of Science ®Google Scholar
• Ataseven A, Temiz SA, Eren G, Özer İ, Dursun R. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J DermatolTreat. 2022;33(2):1091–1096. doi:10.1080/09546634.2020.1801975
   Google Scholar
• Nast A, Smith C, Spuls PI, et al. EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris - part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol. 2021;35(2):281–317. doi:10.1111/jdv.16926
   PubMed Web of Science ®Google Scholar